Business Overview: Citius Oncology, Inc. (Nasdaq: CTOR)

---

Executive Summary

Citius Oncology is a newly commercial-stage biopharmaceutical company built around a single approved oncology product: LYMPHIR (denileukin diftitox-cxdl), an engineered interleukin-2 diphtheria toxin fusion protein for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy. The company was spun out of Citius Pharmaceuticals in an August 2024 reverse-merger transaction, and Citius Pharmaceuticals remains the controlling shareholder, owning approximately 77.9% of Citius Oncology as of December 2025. LYMPHIR received FDA approval in August 2024 and was commercially launched in December 2025, giving the company only a few months of real-world sales history — the company announced its first reported product revenue in February 2026.

The business model is a classic single-asset specialty-pharma launch: Citius Oncology has built a targeted U.S. sales force calling on major cancer centers and key opinion leaders to drive LYMPHIR adoption in a niche, orphan-adjacent indication (CTCL) where it estimates a U.S. addressable market of over $400 million, while pursuing ex-U.S. partnerships and investigator-initiated combination trials (with CAR-T and pembrolizumab) to expand the product's long-term utility and geographic reach. Critically, the company itself has zero employees — commercial, clinical, and administrative operations are run by roughly 30-plus Citius Pharmaceuticals personnel under a shared-services agreement, meaning Citius Oncology's operational independence from its parent is limited even though it trades as a separately listed public company.

The single most decision-relevant fact for investors is that Citius Oncology's auditors have raised substantial doubt about its ability to continue as a going concern: as of the most recent 10-K reporting date the company held only $3.9 million of cash against an accumulated deficit of $64 million, a fiscal 2025 net loss of $24.7 million, and over $60 million of combined license and supplier obligations (Eisai and Dr. Reddy's), with management estimating a cash runway only into March 2026 before additional capital raises. The company has since raised roughly $30 million gross (including an $18 million raise in December 2025) and begun generating its first LYMPHIR sales, but the fundamental investment thesis remains a race between early commercial ramp and the company's ability to keep funding operations — the 10-K itself warns that failure to complete financing or partnership transactions could force the Board toward dissolution and liquidation.

---

1. Core Business Model & How They Work

Citius Oncology generates (or, historically, expects to generate) revenue from direct U.S. sales of LYMPHIR to hospitals, infusion centers, and specialty pharmacies serving CTCL patients, supplemented by royalty and milestone economics from prospective ex-U.S. licensing partnerships. As a single-product commercial-stage biopharma, essentially all value creation depends on the depth and speed of LYMPHIR's adoption curve in a narrow, well-defined patient population, the durability of its clinical response profile relative to existing therapies, and the company's ability to fund a specialty sales force and manufacturing/supply obligations while revenue ramps from a standing start.

Key Operational Drivers

1. LYMPHIR Commercial Launch — FDA-approved August 2024, launched December 2025, with first reported revenue announced in February 2026; commercial success depends on physician adoption at key academic and community cancer centers.
2. Targeted Specialty Sales Infrastructure — a dedicated sales force calling on the concentrated set of cancer centers that treat CTCL, an approach suited to the disease's low incidence but requiring sustained cash investment before reaching breakeven volume.
3. Reimbursement Pathway — LYMPHIR's inclusion in NCCN treatment guidelines (September 2024) and assignment of a dedicated HCPCS J-code (J9161, February 2025) are important commercial enablers that support payer reimbursement and physician ordering.
4. Parent-Company Dependency — the company has zero direct employees and relies on a shared-services agreement with Citius Pharmaceuticals (which owns ~77.9% of CTOR) for essentially all operational, clinical, regulatory, and G&A functions, creating both efficiency (no duplicated infrastructure) and governance/conflict-of-interest risk.
5. Life-Cycle Expansion via Combination Trials — investigator-initiated Phase 1/1b studies combining LYMPHIR with CAR-T therapy (University of Minnesota) and pembrolizumab (University of Pittsburgh, showing an early 27% ORR signal) aim to expand LYMPHIR's addressable use beyond monotherapy in relapsed/refractory CTCL.

---

2. Business Segments

Citius Oncology operates as a single-product, single-segment biopharmaceutical business; it does not report discrete operating segments. All commercial and development activity centers on LYMPHIR and its potential combination-therapy and geographic label expansions.

---

3. Product Portfolio

---

4. Competitive Landscape

LYMPHIR competes in the small but growing systemic-therapy market for cutaneous T-cell lymphoma, where several already-approved therapies address an overlapping relapsed/refractory patient population. Because CTCL is a rare disease, the competitive set is narrow but entrenched — oncologists have years of clinical experience with existing agents, and LYMPHIR must displace or supplement established treatment sequencing based on differentiated efficacy, tolerability, or dosing convenience. The company's own disclosures frame the opportunity as one of "significant unmet medical need" despite existing options, reflecting real but incomplete efficacy and durability with current therapies.

Key Competitors / Existing CTCL Therapies:

• Mogamulizumab (Poteligeo) — Kyowa Kirin
• Brentuximab vedotin (Adcetris) — Pfizer/Seagen
• Romidepsin (Istodax) — generic/branded HDAC inhibitor
• Vorinostat (Zolinza) — generic/branded HDAC inhibitor
• Broader oncology/immuno-oncology pipelines from larger biopharma companies that could enter CTCL or overlapping T-cell lymphoma indications over time

Citius Oncology's key competitive vulnerability is scale: as a single-product company with no in-house infrastructure beyond a lean commercial team, it cannot match the marketing reach, manufacturing redundancy, or balance-sheet resilience of the larger, diversified oncology companies that market competing CTCL therapies.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• FDA approval and inclusion in NCCN guidelines provide a real, if narrow, regulatory and clinical-credibility barrier to new entrants in this specific indication.
• Differentiated mechanism (IL-2 diphtheria toxin fusion protein) and clinical data (36% ORR, meaningful complete-response rate) offer physicians an additional treatment option in a disease with genuine unmet need.
• Dedicated HCPCS J-code (J9161) removes a common early-launch reimbursement hurdle that can otherwise slow specialty-drug adoption.
• Operational leverage from the Citius Pharmaceuticals shared-services relationship avoids duplicating clinical, regulatory, and administrative infrastructure that a fully standalone launch would require.

Strategic Risks & Vulnerabilities

1. Going-concern doubt and thin liquidity — $3.9 million of cash against a $24.7 million annual net loss and over $60 million of license/supplier obligations left the company reliant on successive capital raises (roughly $30 million gross through December 2025) just to fund early commercialization.
2. Single-product concentration — with no marketed products beyond LYMPHIR and no other late-stage pipeline assets, any setback in commercial uptake, manufacturing supply, or safety signal would jeopardize the entire company.
3. Parent-company dependency and conflicts of interest — zero direct employees and majority ownership (~77.9%) by Citius Pharmaceuticals create structural reliance on a related party for operations and raise potential conflicts in capital-allocation and strategic decisions.
4. Heavy contractual milestone and royalty obligations — up to $40 million in CTCL approval milestones, $70 million in development milestones, and $300 million in commercial milestones owed to Dr. Reddy's (plus 10-15% tiered royalties), together with Eisai license payments, will consume a substantial share of future LYMPHIR revenue before it reaches the company's bottom line.
5. Narrow disease population — CTCL is a rare disease, meaning peak sales potential is inherently capped versus larger oncology indications, and the estimated >$400 million U.S. addressable market leaves limited room for error in capturing share.

---

6. Financial Overview

---

7. Summary Conclusion

Citius Oncology represents a high-risk, single-asset commercial-stage biopharma story: it has cleared the hardest regulatory hurdle (FDA approval of LYMPHIR) and reached the market with a differentiated therapy for a rare, underserved cancer, but it did so with minimal capital cushion and structural dependence on its majority owner, Citius Pharmaceuticals, for virtually all operations. The company's own auditors have flagged going-concern risk, and while early 2026 developments — the LYMPHIR launch, first reported revenue, and successive capital raises — suggest management is executing the commercialization playbook, the balance sheet remains thin relative to tens of millions of dollars in license and supply obligations. The investment case hinges almost entirely on how quickly LYMPHIR's sales ramp in its narrow CTCL indication (and potentially through combination-therapy expansion) relative to the company's ongoing cash burn; absent a faster-than-expected commercial ramp, sizable partnership deal, or further dilutive financing, the risk of continued shareholder dilution or a forced strategic transaction remains elevated.